Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 8/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 8/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 7/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.76 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.76 |
| ▸ | PTAFR | P25105 | 8/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724655 | 0.90 | GABRA1 (0.82) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL2874506 | 0.88 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL7722603 | 0.88 | GABRA1 (0.78) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL3138147 | 0.87 | GABRA1 (0.76) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL2843952 | 0.87 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| Triazolam SCHEMBL29368430 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| Triazolam SCHEMBL29228 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL13352295 | 0.86 | GABRA1 (0.83) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| Triazolam SCHEMBL29382425 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| Triazolam SCHEMBL29349744 | 0.86 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020036-A1 | TREATMENT OF EPILEPTIC CONDITIONS WITH GABAA RECEPTOR MODULATORS | NEUROCYCLE THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220152037-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | NEUROCYCLE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-10786513-B2 | Use of GABAA receptor modulators for treatment of itch | UNIVERSITAT ZURICH (CH) | 2020-09-29 | — | — | US | disclosed |
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190134057-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | UNIVERSITAT ZURICH (CH) | 2019-05-09 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| EP-1490344-B1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC SIDE EFFECTS | WISYS TECHNOLOGY FOUND INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-0320992-B1 | Triazolodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 1994-07-27 | — | — | EP | disclosed |
| US-4959361-A | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists | HOFFMANN-LA ROCHE INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0320992-A2 | Triazolodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20190134057-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF ITCH | GABRB2, GABRB3, GABRB1 | GABRA1 11/4885GABRA5 14/4885GABRA2 7/4885 |
| US-20100317619-A1 | Selective Agents for Pain Suppression | CNR2, CNR1, OPRL1 | GABRA1 12/4885GABRA5 5/4885GABRA2 9/4885 |
| US-20230020036-A1 | TREATMENT OF EPILEPTIC CONDITIONS WITH GABAA RECEPTOR MODULATORS | GABRB2, GABRB1, GABBR1 | GABRA1 10/4885GABRA5 8/4885GABRA2 6/4885 |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-10786513-B2 | Use of GABAA receptor modulators for treatment of itch | GABRB2, GABRB3, GABRB1 | GABRA1 11/4885GABRA5 15/4885GABRA2 7/4885 |
| US-20220152037-A1 | USE OF GABAA RECEPTOR MODULATORS FOR TREATMENT OF PAIN | GABRB2, GABRB1, GABBR1 | GABRA1 6/4885GABRA5 14/4885GABRA2 5/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRA1 5/4885GABRA5 6/4885GABRA2 4/4885 |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | GABRA1 4/4885GABRA5 1/4885GABRA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.